PURPOSE Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet...

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. Jul 02, 2026 10.1200/jco-25-02735

PURPOSE Prognosis in low-grade gliomas (LGGs) remains highly variable, and treatment-related late toxicity is a concern. This trial was comparing single-modality therapies in patie...

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma

Ariel E. Marciscano, Helen A. Shih Jul 02, 2026 10.1200/jco-26-00771

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Curtis A. Lachowiez, Joshua F. Zeidner, Jad Othman et al. Jul 02, 2026 10.1200/jco-26-00347

PURPOSE As risk stratification for patients with AML treated with lower-intensity venetoclax-based therapy remains suboptimal, we developed and validated a prognostic model integra...

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial

James M. Cleary, Christoph Springfeld, Dirk Arnold et al. Jul 01, 2026 10.1200/jco-25-03128

PURPOSE Presently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion–positive ( NRG1...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2

Sonam Puri, Nofisat Ismaila, Ibrahim Hanna Azar et al. Jun 29, 2026 10.1200/jco-26-01479

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

Takeshi Kodaira, Yukinori Asada, Yuji Hirayama et al. Jun 26, 2026 10.1200/jco-25-01708

The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in...

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial

Song Li, Zimin Liu, Yanguo Liu et al. Jun 26, 2026 10.1200/jco-26-00277

PURPOSE Clinical data for first-line combination of antibody-drug conjugates (ADC) and immune checkpoint inhibitors in human epidermal growth factor receptor 2 (HER2)–overexpressin...

All Issues

Issue 9 - Issue 9 14 Issue 8 - Issue 8 16 Issue 7_suppl - Issue 7_suppl 886 Issue 7 - Issue 7 17 Issue 6 - Issue 6 15 Issue 5 - Issue 5 15 Issue 4 - Issue 4 13 Issue 3 - Issue 3 13 Issue 24 - Issue 24 18 Issue 23 - Issue 23 16 Issue 22 - Issue 22 15 Issue 21 - Issue 21 14 Issue 20 - Issue 20 18 Issue 2_suppl - Issue 2_suppl 818 Issue 2 - Issue 2 12 Issue 19_suppl - Issue 19_suppl 340 Issue 19 - Issue 19 16 Issue 18 - Issue 18 16 Issue 17_suppl - Issue 17_suppl 60 Issue 17 - Issue 17 17 Issue 16_suppl - Issue 16_suppl 7213 Issue 16 - Issue 16 15 Issue 15 - Issue 15 13 Issue 14 - Issue 14 14 Issue 13 - Issue 13 14 Issue 12 - Issue 12 16 Issue 11 - Issue 11 15 Issue 10 - Issue 10 14 Issue 1 - Issue 1 11

Issue 9 - Issue 9 15 Issue 8 - Issue 8 19 Issue 7 - Issue 7 19 Issue 6 - Issue 6 20 Issue 5_suppl - Issue 5_suppl 869 Issue 5 - Issue 5 21 Issue 4_suppl - Issue 4_suppl 824 Issue 4 - Issue 4 18 Issue 36 - Issue 36 12 Issue 35 - Issue 35 12 Issue 34 - Issue 34 12 Issue 33 - Issue 33 14 Issue 32 - Issue 32 17 Issue 31 - Issue 31 16 Issue 30 - Issue 30 14 Issue 3 - Issue 3 17 Issue 29 - Issue 29 16 Issue 28 - Issue 28 16 Issue 27 - Issue 27 14 Issue 26 - Issue 26 13 Issue 25 - Issue 25 17 Issue 24 - Issue 24 19 Issue 23 - Issue 23 14 Issue 22 - Issue 22 14 Issue 21 - Issue 21 13 Issue 20 - Issue 20 12 Issue 2 - Issue 2 18 Issue 19 - Issue 19 12 Issue 18 - Issue 18 14 Issue 17_suppl - Issue 17_suppl 57 Issue 17 - Issue 17 15 Issue 16_suppl - Issue 16_suppl 6439 Issue 16 - Issue 16 14 Issue 15 - Issue 15 16 Issue 14 - Issue 14 17 Issue 13 - Issue 13 17 Issue 12 - Issue 12 15 Issue 11 - Issue 11 18 Issue 10 - Issue 10 14 Issue 1 - Issue 1 20

Issue 1 - Issue 1 113

Journal Info

Publisher Lippincott Williams & Wilkins

ISSN 0732-183X

E-ISSN 1527-7755

Subject Health Sciences

Language English

View Full Journal Page

Journal of Clinical Oncology

Articles in this Issue

Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?

Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743

Reply to: The Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers

Reply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer

Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers

PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer

Still Lost in Transition? A 20-Year Reflection on Cancer Survivorship Care

Uncontrolled Prediabetes Confounding in the Association Between Alcohol Consumption and Young-Onset Pancreatic Cancer

Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer

Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy

Reply to: “Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer” and “Uncontrolled Prediabetes Confounding in the Association Between Alcohol Consumption and Young-Onset Pancreatic Cancer”

Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial

EXTENDing the Role of Radiation in Oligometastatic Disease

Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?

Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?

Care Gap: Identifying and Bridging Barriers in Primary Palliative Care

Sustaining High Reliability Amid Artificial Intelligence Adoption in Oncology

All Issues

Journal Info